Notice of Class Action Lawsuit Against ADMA Biologics Securities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 58 minutes ago
0mins
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the filed class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false or misleading statements during the class period, including undisclosed related party transactions and channel stuffing practices, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
- Investor Action Recommendations: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their interests and avoid inexperienced intermediaries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of Class Action Lawsuit Against ADMA Biologics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the filed class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false or misleading statements during the class period, including undisclosed related party transactions and channel stuffing practices, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
- Investor Action Recommendations: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their interests and avoid inexperienced intermediaries.
See More
ADMA Biologics Faces Securities Fraud Class Action Lawsuit
- Lawsuit Overview: A class action lawsuit has been filed against ADMA Biologics for securities fraud, alleging significant misstatements and omissions in financial reporting during the period from August 9, 2024, to March 25, 2026, which undermines investor confidence.
- Stock Price Plunge: Following a report by Culper Research on March 24, 2026, alleging 'channel stuffing', ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, reflecting market concerns about the company's financial health.
- Investor Action: Investors have until August 10, 2026, to apply for lead plaintiff status to represent other investors in the lawsuit, with KTMC offering free case evaluations, emphasizing that investors' rights to recovery are unaffected by their decision to serve as lead plaintiffs.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a prominent law firm specializing in securities fraud class actions, having recovered over $25 billion for clients and represented major institutional investors, showcasing its strong capabilities and influence in securities litigation.
See More
Reminder of Securities Fraud Lawsuit Against ADMA Biologics
- Lawsuit Background: A securities fraud class action lawsuit against ADMA Biologics was filed on March 25, 2026, alleging undisclosed related party transactions and channel stuffing to inflate revenues during the period from August 9, 2024, to March 25, 2026, which has negatively impacted investor confidence.
- Stock Price Volatility: On March 24, 2026, ADMA's stock price dropped by $2.26, approximately 17%, from $13.59 to $11.33 due to a short seller report, with further declines to $9.63 the next day, reflecting market concerns over the company's financial transparency.
- Rating Downgrade: On March 26, 2026, Cantor Fitzgerald downgraded ADMA's rating due to pressure from the short report, highlighting the company's failure to clearly address allegations of revenue inflation, leading to an additional drop of $1.34 in stock price, exacerbating investor anxiety.
- Investor Action: Investors must apply for lead plaintiff status by August 10, 2026, to represent collective interests in the lawsuit, as courts typically appoint individual investors as lead plaintiffs, underscoring the significance of investor participation in the litigation process.
See More
Reminder for ADMA Biologics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiff by August 10, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false or misleading statements during the class period, including undisclosed related party transactions and channel stuffing to inflate revenue, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
- Investor Selection Advice: Investors are advised to carefully select law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Reminder for ADMA Biologics Investors on Class Action Lawsuit
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that August 10, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026.
- Allegations: A report by Culper Research alleges that ADMA engaged in 'channel stuffing' and undisclosed related party transactions, resulting in a real growth rate of -3% in 2025 compared to the reported 20%, which has led to significant investor losses.
- Stock Price Impact: Following this news, ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, which severely harmed investor interests.
- Legal Claims: The lawsuit alleges that ADMA made materially false and misleading statements throughout the class period, failing to disclose adverse facts about its business, operations, and prospects, which has significantly undermined investor confidence in the company.
See More
Investor Alert: Class Action Lawsuit Notices
- Lawsuit Timeline: The class action lawsuit for Via Transportation, Inc. covers the period from September 9, 2025, to June 9, 2026, with a lead plaintiff deadline of August 10, 2026, meaning investors must act promptly to avoid losing their rights to claim.
- False Statements Allegations: The lawsuit alleges that Via Transportation's management made materially false and misleading statements during this period, failing to disclose a decline in annual recurring revenue per customer and regulatory issues that could hinder its expansion strategy in Germany, negatively impacting the company's future business outlook.
- Zillow Class Action: Zillow Group, Inc. has a class action lawsuit covering the period from February 11, 2025, to May 7, 2026, with a similar lead plaintiff deadline of August 10, 2026, emphasizing the need for investors to act quickly to preserve their rights.
- Antitrust Risks: The lawsuit claims that Zillow failed to disclose that its agreement with Redfin was an acquisition rather than a partnership, and downplayed legal exposure amid an antitrust lawsuit, which could severely impact its stock price and market confidence.
See More
Notice of Class Action Lawsuit Against ADMA Biologics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the filed class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false or misleading statements during the class period, including undisclosed related party transactions and channel stuffing practices, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
- Investor Action Recommendations: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their interests and avoid inexperienced intermediaries.
See More
ADMA Biologics Faces Securities Fraud Class Action Lawsuit
- Lawsuit Overview: A class action lawsuit has been filed against ADMA Biologics for securities fraud, alleging significant misstatements and omissions in financial reporting during the period from August 9, 2024, to March 25, 2026, which undermines investor confidence.
- Stock Price Plunge: Following a report by Culper Research on March 24, 2026, alleging 'channel stuffing', ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, reflecting market concerns about the company's financial health.
- Investor Action: Investors have until August 10, 2026, to apply for lead plaintiff status to represent other investors in the lawsuit, with KTMC offering free case evaluations, emphasizing that investors' rights to recovery are unaffected by their decision to serve as lead plaintiffs.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a prominent law firm specializing in securities fraud class actions, having recovered over $25 billion for clients and represented major institutional investors, showcasing its strong capabilities and influence in securities litigation.
See More
Reminder of Securities Fraud Lawsuit Against ADMA Biologics
- Lawsuit Background: A securities fraud class action lawsuit against ADMA Biologics was filed on March 25, 2026, alleging undisclosed related party transactions and channel stuffing to inflate revenues during the period from August 9, 2024, to March 25, 2026, which has negatively impacted investor confidence.
- Stock Price Volatility: On March 24, 2026, ADMA's stock price dropped by $2.26, approximately 17%, from $13.59 to $11.33 due to a short seller report, with further declines to $9.63 the next day, reflecting market concerns over the company's financial transparency.
- Rating Downgrade: On March 26, 2026, Cantor Fitzgerald downgraded ADMA's rating due to pressure from the short report, highlighting the company's failure to clearly address allegations of revenue inflation, leading to an additional drop of $1.34 in stock price, exacerbating investor anxiety.
- Investor Action: Investors must apply for lead plaintiff status by August 10, 2026, to represent collective interests in the lawsuit, as courts typically appoint individual investors as lead plaintiffs, underscoring the significance of investor participation in the litigation process.
See More
Reminder for ADMA Biologics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiff by August 10, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false or misleading statements during the class period, including undisclosed related party transactions and channel stuffing to inflate revenue, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
- Investor Selection Advice: Investors are advised to carefully select law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Reminder for ADMA Biologics Investors on Class Action Lawsuit
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that August 10, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026.
- Allegations: A report by Culper Research alleges that ADMA engaged in 'channel stuffing' and undisclosed related party transactions, resulting in a real growth rate of -3% in 2025 compared to the reported 20%, which has led to significant investor losses.
- Stock Price Impact: Following this news, ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, which severely harmed investor interests.
- Legal Claims: The lawsuit alleges that ADMA made materially false and misleading statements throughout the class period, failing to disclose adverse facts about its business, operations, and prospects, which has significantly undermined investor confidence in the company.
See More
Investor Alert: Class Action Lawsuit Notices
- Lawsuit Timeline: The class action lawsuit for Via Transportation, Inc. covers the period from September 9, 2025, to June 9, 2026, with a lead plaintiff deadline of August 10, 2026, meaning investors must act promptly to avoid losing their rights to claim.
- False Statements Allegations: The lawsuit alleges that Via Transportation's management made materially false and misleading statements during this period, failing to disclose a decline in annual recurring revenue per customer and regulatory issues that could hinder its expansion strategy in Germany, negatively impacting the company's future business outlook.
- Zillow Class Action: Zillow Group, Inc. has a class action lawsuit covering the period from February 11, 2025, to May 7, 2026, with a similar lead plaintiff deadline of August 10, 2026, emphasizing the need for investors to act quickly to preserve their rights.
- Antitrust Risks: The lawsuit claims that Zillow failed to disclose that its agreement with Redfin was an acquisition rather than a partnership, and downplayed legal exposure amid an antitrust lawsuit, which could severely impact its stock price and market confidence.
See More
